Key facts, as of
As of September 29, 2026, Biogen Inc. (BIIB) trades at $227.07, up 63.9% over the past year. Its 52-week range runs from $136.94 to $230.49; the price is 1.5% below that high. It sits 16.8% above its 200-day average of $194.46, the usual sign of a long-term uptrend. Its 30-day volatility is 25.2% annualized, which we rate medium risk. It has a trailing P/E of 40.4.
Cite: Portfolio Terminal, "Biogen Inc. (BIIB) stock analysis", 2026-09-29. https://portfolio-terminal.com/analyse/biib
Where it trades today
trading 96% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- BIIB trades at 40.4x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- BIIB carries a beta of 0.17, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- BIIB is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in BIIB.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
Methodology
- Price, market cap, beta, yield, and liquidity fields for BIIB come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for BIIB. Last refresh: Sep 29, 2026, 10:33 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Biogen Inc. does
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat…
Employees
7,500
Industry
Drug Manufacturers - General
Headquarters
Cambridge, United States
What analysts expect
BIIB carries a buy consensus from 31 analysts, with an average price target of $238.18 versus $227.07 today (+4.9%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
BIIB generated $10.03B in trailing revenue (3.4% year over year), with a 8.3% net margin, and $1.27B of free cash flow, against $7.07B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $9.89B | $7.49B | $2.47B | $1.29B | $8.83 | $1.97B |
| 2024 | $9.68B | $7.37B | $2.28B | $1.63B | $11.21 | $2.52B |
| 2023 | $9.84B | $7.30B | $1.85B | $1.16B | $8.02 | $1.24B |
| 2022 | $10.17B | $7.90B | $2.90B | $3.05B | $20.96 | $1.14B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
BIIB beside the healthcare names it is usually measured against.
What the chart is saying
In an uptrend, 1.5% under its 1-year high with no resistance above.
uptrend- Price is 6.1% above its 50-day average and 16.8% above its 200-day.
- RSI at 61 is neither stretched nor washed out.
- Nothing above has stopped it this year; the nearest floor is $224.33 (-1.2%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is BIIB a good buy right now?
Biogen Inc. trades at 40.4x earnings. This is above market average, reflecting growth expectations. Current risk level is Medium based on 25.2% volatility.
Does BIIB pay dividends?
Biogen Inc. does not currently pay a regular dividend. The company may be reinvesting profits for growth.
How volatile is BIIB?
With 30-day annualized volatility of 25.2% and beta of 0.17, BIIB is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for BIIB?
The average analyst price target for Biogen Inc. (BIIB) is $238.18 based on 31 analyst estimates, about 4.9% above the current price of $227.07. The published range runs from $175.00 to $300.00.
How much revenue does BIIB generate?
Biogen Inc. reported $10.03B in trailing twelve-month revenue. Revenue growth is running at 3.4% year over year. Net margin sits at 8.3%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare BIIB with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.